The effects of the GABA agonist, baclofen, on sleep and breathing

The gamma aminobutyric acid (GABA)-B agonist, baclofen, is a centrally-acting, anti-spasmodic agent and muscle relaxant used in spinal cord lesions, multiple sclerosis and other neurological disorders. In a previous pilot study of quadriplegic patients, 75% of whom were treated with baclofen, we found a high prevalence of sleep-disordered breathing. Because of the depressant effects of GABA on the central nervous system, we hypothesized that baclofen might aggravate sleep-disordered breathing in susceptible individuals by depressing central ventilatory drive, increasing upper airway obstruction and/or increasing the arousal threshold to apnoea. We therefore conducted a double-blind, placebo-controlled, cross-over study of baclofen 25 mg, administered before sleep in 10 snorers with mild sleep-disordered breathing (respiratory disturbance index < 30 events per sleep hour). Each subject underwent two standard polysomnographic assessments, one week apart. Total sleep time was significantly prolonged by baclofen (placebo 356 +/- 9.9 SEM min; baclofen 386 +/- 9.9 min). Both nonrapid eye movement(REM) and REM sleep duration were increased (nonREM: placebo 295 +/- 6.8 min; baclofen 311 +/- 8.9 min; REM: placebo 61 +/- 7.5 min; baclofen 76 +/- 9.0 min). Time spent awake after sleep onset was reduced after baclofen (placebo 71 +/- 10.3 min; baclofen 51 +/- 9.7 min). There was a slight reduction in mean overnight oxygen saturation (placebo 95.2 +/- 0.5%; baclofen 94.4 +/- 0.7%). The frequency of apnoeas plus hypopnoeas (respiratory disturbance index (RDI)) did not change significantly (placebo 9 +/- 1.8 events.h-1; baclofen 13 +/- 3.4 events.h-1).(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				T. Matsuki, M. Nomiyama, H. Takahira, N. Hirashima, S. Kunita, S. Takahashi, K.-i. Yagami, T. S. Kilduff, B. Bettler, M. Yanagisawa, et al. Selective loss of GABAB receptors in orexin-producing neurons results in disrupted sleep/wakefulness architecture PNAS, March 17, 2009; 106(11): 4459 - 4464. [Abstract] [Full Text] [PDF]

				D. Bensmail, M. A. Q. Salva, N. Roche, S. Benyahia, M. Bohic, P. Denys, B. Bussel, and F. Lofaso Effect of intrathecal baclofen on sleep and respiratory function in patients with spasticity Neurology, October 24, 2006; 67(8): 1432 - 1436. [Abstract] [Full Text] [PDF]

				X. Xie, T. L. Crowder, A. Yamanaka, Stephen. R. Morairty, R. D. LeWinter, T. Sakurai, and T. S. Kilduff GABAB receptor-mediated modulation of hypocretin/orexin neurones in mouse hypothalamus J. Physiol., July 15, 2006; 574(2): 399 - 414. [Abstract] [Full Text] [PDF]

				T. Saaresranta and O. Polo Hormones and Breathing Chest, December 1, 2002; 122(6): 2165 - 2182. [Abstract] [Full Text] [PDF]

				D. W. HUDGEL and S. THANAKITCHARU Pharmacologic Treatment of Sleep-disordered Breathing Am. J. Respir. Crit. Care Med., September 1, 1998; 158(3): 691 - 699. [Abstract] [Full Text] [PDF]